Melanoma and Epigenetic Treatment: Past and Future

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Melanoma and Epigenetic Treatment: Past and Future

Anti-Cancer Agents in Medicinal Chemistry, 12(3): 202-209.

Author(s): Caterina AM La Porta.

Affiliation: Laboratory of Molecular Oncology, Department of Biomolecular Science and Biotechnology,University of Milan.


Melanoma is the most aggressive form of skin cancer and advanced stages are inevitably resistant to conventional therapeutic agents. In particular, epigenetic strategies might open interesting new perspectives in combination with conventional ones. Current therapeutic strategies, in particular for metastatic melanoma, do not give great results in terms of survival. Herein, I review HDACis and microRNAs for melanoma. A critical discussion of all the recent findings on this topic is also included. In my view, further studies are needed to understand the toxicity of these treatments in order to improve survival of melanoma patients.


Melanoma, Epigenetic, microRNAs, CHEMOTHERAPIC AGENTS, nucleosomes, HDAC Inhibitor, acetylation, methylation, phosphorylation, ubiquitination.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 12
Issue Number: 3
First Page: 202
Last Page: 209
Page Count: 8
DOI: 10.2174/187152012800228760
Price: $58
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: Copyright © 2017 Bentham Science